Safety Study of Ranibizumab Eye Injections to Treat Choroidal Neovascularization That Was Caused Other Than by Age-Related Macular Degeneration.

Ophthalmic Consultants of Boston30 enrolled

Overview

The purpose of this study is to determine whether ranibizumab is effective in the treatment of choroidal neovascularization secondary to causes other then wet macular-degeneration.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Choroidal Neovascularization

Interventions

ranibizumabDRUG

0.5mg intravitreal injection

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * active choroidal neovascularization Exclusion Criteria: * pregnancy,age-related macular degeneration, current eye infection or recent eye surgery, participating in other eye studies

Outcomes

Primary Outcomes

The primary outcome measures for safety and tolerability

Time frame: Mean change in visual acuity from baseline to 6 months & 12 months

Secondary Outcomes

The secondary outcome measures for efficacy

Time frame: Mean change in visual acuity from baseline to 6 & 12 months. Change in retinal thickness from baseline to week 1, month 1, 2, 3, 6, & 12 measured by OCT. Change in area of CNV from baseline to month 3, 6 & 12 measured by FA

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.